
|Articles|March 1, 2004
Illuminating therapies
Washington, D.C. - Ongoing work regarding aminolevulinic acid (ALA) for photodynamic therapy provides a shining example of the value of off-label uses. The drug has earned UK approval for treating skin cancer and FDA approval for actinic keratoses. However, its most effective applications may well be cosmetic treatments including photo-rejuvenation, acne, and sebaceous gland hyperplasia.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5


















